{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:53:06Z","timestamp":1791525186643,"version":"4.3.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04970-1","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:46:09Z","timestamp":1791524769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification"],"prefix":"10.1007","volume":"96","author":[{"given":"Sanket","family":"Nagmoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshita","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Sakle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad","family":"Kapare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-3441","authenticated-orcid":false,"given":"Pawan N.","family":"Karwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"3","key":"4970_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21(3):181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4970_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target therapy 7(1):113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"4970_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X (2024) Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target therapy 9(1):308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x","journal-title":"Signal Transduct Target therapy"},{"key":"4970_CR4","doi-asserted-by":"publisher","unstructured":"Lavanya V, Adil M, Ahmed N, Rishi AK, Jamal S (2014) Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Ther 1(3):39\u201346. https:\/\/doi.org\/10.15761\/ICST.1000109","DOI":"10.15761\/ICST.1000109"},{"issue":"2","key":"4970_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/atm-25-34","volume":"13","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia M, Weiskirchen R (2025) Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment. Annals translational Med 13(2):18. https:\/\/doi.org\/10.21037\/atm-25-34","journal-title":"Annals translational Med"},{"issue":"5","key":"4970_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","volume":"38","author":"D Ho","year":"2020","unstructured":"Ho D, Quake SR, McCabe ER, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC (2020) Enabling technologies for personalized and precision medicine. Trends Biotechnol 38(5):497\u2013518. https:\/\/doi.org\/10.1016\/j.tibtech.2019.12.021","journal-title":"Trends Biotechnol"},{"issue":"6","key":"4970_CR7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-13-2961","volume":"20","author":"DR Parkinson","year":"2014","unstructured":"Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, DeVerka P, Frueh FW, Jessup JM, McShane LM (2014) Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 20(6):1428\u20131444. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2961","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4970_CR8","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/cancers15153837","volume":"15","author":"RC Wang","year":"2023","unstructured":"Wang RC, Wang Z (2023) Precision medicine: disease subtyping and tailored treatment. Cancers 15(15):3837. https:\/\/doi.org\/10.3390\/cancers15153837","journal-title":"Cancers"},{"issue":"7","key":"4970_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/genes11070747","volume":"11","author":"O Strianese","year":"2020","unstructured":"Strianese O, Rizzo F, Ciccarelli M, Galasso G, D\u2019Agostino Y, Salvati A, Del Giudice C, Tesorio P, Rusciano MR (2020) Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes 11(7):747. https:\/\/doi.org\/10.3390\/genes11070747","journal-title":"Genes"},{"issue":"3","key":"4970_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/pharmaceutics16030332","volume":"16","author":"L Marques","year":"2024","unstructured":"Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalh\u00e3es P, Schmidt S, Vale N (2024) Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics 16(3):332. https:\/\/doi.org\/10.3390\/pharmaceutics16030332","journal-title":"Pharmaceutics"},{"key":"4970_CR11","doi-asserted-by":"publisher","unstructured":"Maltsev D, Tyravska Y, Shpryakha Y, Merzliak SV Individualised medicine: Application of a personalised approach in clinical practice. https:\/\/doi.org\/10.47310\/jpms2025140602","DOI":"10.47310\/jpms2025140602"},{"key":"4970_CR12","doi-asserted-by":"publisher","unstructured":"Berry CT, Frazee CS, Herman PJ, Chen S, Chen A, Kuo Y, Ellebrecht CT Current advancements in cellular immunotherapy for autoimmune disease. InSeminars in immunopathology 2025 Dec (Vol. 47, No. 1, p. 7). Berlin\/Heidelberg: Springer Berlin Heidelberg. https:\/\/doi.org\/10.1007\/s00281-024-01034-5","DOI":"10.1007\/s00281-024-01034-5"},{"issue":"8","key":"4970_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","volume":"27","author":"DA Nalawansha","year":"2020","unstructured":"Nalawansha DA, Crews CM (2020) PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem biology 27(8):998\u20131014. https:\/\/doi.org\/10.1016\/j.chembiol.2020.07.020","journal-title":"Cell Chem biology"},{"issue":"7","key":"4970_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","volume":"28","author":"KT Samarasinghe","year":"2021","unstructured":"Samarasinghe KT, Crews CM (2021) Targeted protein degradation: A promise for undruggable proteins. Cell Chem biology 28(7):934\u2013951. https:\/\/doi.org\/10.1016\/j.chembiol.2021.04.011","journal-title":"Cell Chem biology"},{"issue":"4","key":"4970_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","volume":"23","author":"KA Rutherford","year":"2024","unstructured":"Rutherford KA, McManus KJ (2024) PROTACs: current and future potential as a precision medicine strategy to combat cancer. Mol Cancer Ther 23(4):454\u2013463. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0747","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"4970_CR16","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.1039\/D4CS00411F","volume":"53","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liu F, Pal S, Hu Q (2024) Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design. Chem Soc Rev 53(19):9582\u20139608. https:\/\/doi.org\/10.1039\/D4CS00411F","journal-title":"Chem Soc Rev"},{"issue":"8","key":"4970_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","volume":"58","author":"S He","year":"2025","unstructured":"He S, Dong G, Sheng C (2025) Strategies for precise modulation of protein degradation. Acc Chem Res 58(8):1236\u20131248. https:\/\/doi.org\/10.1021\/acs.accounts.5c00003","journal-title":"Acc Chem Res"},{"issue":"31","key":"4970_CR18","doi-asserted-by":"publisher","first-page":"e202507702","DOI":"10.1002\/ange.202507702","volume":"137","author":"X Zhang","year":"2025","unstructured":"Zhang X, Song Z, Zhang X, Zou J, Yu G, Chen X, Wang S (2025) Unconventional PROTACs for targeted protein degradation in cancer therapy. Angew Chem 137(31):e202507702. https:\/\/doi.org\/10.1002\/ange.202507702","journal-title":"Angew Chem"},{"issue":"1","key":"4970_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM (2020) Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181(1):102\u2013114. https:\/\/doi.org\/10.1016\/j.cell.2019.11.031","journal-title":"Cell"},{"issue":"2","key":"4970_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","volume":"61","author":"I Churcher","year":"2018","unstructured":"Churcher I (2018) Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem 61(2):444\u2013452. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01272","journal-title":"J Med Chem"},{"issue":"1","key":"4970_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, Tong Y, Rao Y (2019) PROTACs: great opportunities for academia and industry. Signal Transduct Target therapy 4(1):64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6","journal-title":"Signal Transduct Target therapy"},{"issue":"8","key":"4970_CR22","doi-asserted-by":"publisher","first-page":"e70197","DOI":"10.1002\/ddr.70197","volume":"86","author":"S Asadi","year":"2025","unstructured":"Asadi S, Taheri-Torbati M, Kesharwani P, Sahebkar A (2025) Lysosome\u2010Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics. Drug Dev Res 86(8):e70197. https:\/\/doi.org\/10.1002\/ddr.70197","journal-title":"Drug Dev Res"},{"issue":"14","key":"4970_CR23","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/d2cs00200k","volume":"51","author":"RG Guenette","year":"2022","unstructured":"Guenette RG, Yang SW, Min J, Pei B, Potts PR (2022) Target and tissue selectivity of PROTAC degraders. Chem Soc Rev 51(14):5740\u20135756. https:\/\/doi.org\/10.1039\/d2cs00200k","journal-title":"Chem Soc Rev"},{"key":"4970_CR24","doi-asserted-by":"publisher","first-page":"101172","DOI":"10.1016\/j.currproblcancer.2024.101172","volume":"54","author":"A Mahajan","year":"2025","unstructured":"Mahajan A, Panzade G, Bhuniya T, Das P, Bhattacharjee B, Das S, Chowdhury A, Chakraborty K, Guha S, Samant A, Dey A (2025) Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics. Curr Probl Cancer 54:101172. https:\/\/doi.org\/10.1016\/j.currproblcancer.2024.101172","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"4970_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/biomedicines14040835","volume":"14","author":"S Guo","year":"2026","unstructured":"Guo S, Liu J, Zheng H, Wu X (2026) Research progress of PROTACs in breast cancer: Subtype-oriented target landscape, clinical stratification evidence, and engineering strategies for translation. Biomedicines 14(4):835. https:\/\/doi.org\/10.3390\/biomedicines14040835","journal-title":"Biomedicines"},{"key":"4970_CR26","doi-asserted-by":"publisher","first-page":"1112159","DOI":"10.3389\/fsoc.2023.1112159","volume":"8","author":"C Delpierre","year":"2023","unstructured":"Delpierre C, Lef\u00e8vre T (2023) Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol 8:1112159. https:\/\/doi.org\/10.3389\/fsoc.2023.1112159","journal-title":"Front Sociol"},{"issue":"15","key":"4970_CR27","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/cancers15153837","volume":"15","author":"RC Wang","year":"2023","unstructured":"Wang RC, Wang Z (2023) Precision medicine: disease subtyping and tailored treatment. Cancers 15(15):3837. https:\/\/doi.org\/10.3390\/cancers15153837","journal-title":"Cancers"},{"issue":"6","key":"4970_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","volume":"14","author":"VB Kraus","year":"2018","unstructured":"Kraus VB (2018) Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol 14(6):354\u2013362. https:\/\/doi.org\/10.1038\/s41584-018-0005-9","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4970_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target therapy 7(1):113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target therapy"},{"key":"4970_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5281\/zenodo.15244690","volume":"2","author":"AG Adepoju","year":"2025","unstructured":"Adepoju AG, Adepoju DA (2025) Biomarker discovery in clinical biology enhances early disease detection, prognosis, and personalized treatment strategies. Int J Adv Res Publ Rev 2:229\u2013252. https:\/\/doi.org\/10.5281\/zenodo.15244690","journal-title":"Int J Adv Res Publ Rev"},{"issue":"12","key":"4970_CR31","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/d2cs00193d","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM (2022) PROTACs: past, present and future. Chem Soc Rev 51(12):5214\u20135236. https:\/\/doi.org\/10.1039\/d2cs00193d","journal-title":"Chem Soc Rev"},{"issue":"15","key":"4970_CR32","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ (2001) Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A 98(15):8554\u20138559. https:\/\/doi.org\/10.1073\/pnas.141230798","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"4970_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N (2015) Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 11(8):611\u2013617. https:\/\/doi.org\/10.1038\/nchembio.1858","journal-title":"Nat Chem Biol"},{"issue":"5","key":"4970_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, Zengerle M, Ciulli A (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13(5):514\u2013521. https:\/\/doi.org\/10.1038\/nchembio.2329","journal-title":"Nat Chem Biol"},{"key":"4970_CR35","doi-asserted-by":"publisher","unstructured":"Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, Zhu H, Farley KA, Ding W, Schiemer J, Feng X (2018) Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci 115(31). https:\/\/doi.org\/10.1073\/pnas.1803662115","DOI":"10.1073\/pnas.1803662115"},{"issue":"1","key":"4970_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target therapy 7(1):113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target therapy"},{"issue":"6241","key":"4970_CR37","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE (2015) Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376\u20131381. https:\/\/doi.org\/10.1126\/science.aab1433","journal-title":"Science"},{"issue":"2","key":"4970_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discovery 16(2):101\u2013114. https:\/\/doi.org\/10.1038\/nrd.2016.211","journal-title":"Nat Rev Drug Discovery"},{"key":"4970_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","volume":"50","author":"SL Paiva","year":"2019","unstructured":"Paiva SL, Crews CM (2019) Targeted protein degradation: elements of PROTAC design. Curr Opin Chem Biol 50:111\u2013119. https:\/\/doi.org\/10.1016\/j.cbpa.2019.02.022","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"4970_CR40","doi-asserted-by":"publisher","first-page":"103395","DOI":"10.1016\/j.drudis.2022.103395","volume":"28","author":"N Guedeney","year":"2023","unstructured":"Guedeney N, Cornu M, Schwalen F, Kieffer C, Voisin-Chiret AS (2023) PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discovery Today 28(1):103395. https:\/\/doi.org\/10.1016\/j.drudis.2022.103395","journal-title":"Drug Discovery Today"},{"key":"4970_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","volume":"57","author":"DP Bondeson","year":"2017","unstructured":"Bondeson DP, Crews CM (2017) Targeted protein degradation by small molecules. Annu Rev Pharmacol Toxicol 57:107\u2013123. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010715-103507","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4970_CR42","doi-asserted-by":"publisher","unstructured":"Dewey JA, Delalande C, Azizi SA, Lu V, Antonopoulos D, Babnigg G (2023) Molecular glue discovery: current and future approaches. J Med Chem 66(14):9278. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00449","DOI":"10.1021\/acs.jmedchem.3c00449"},{"issue":"4","key":"4970_CR43","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/anie.201914396","volume":"59","author":"A Testa","year":"2020","unstructured":"Testa A, Hughes SJ, Lucas X, Wright JE, Ciulli A (2020) Structure-based design of a macrocyclic PROTAC. Angew Chem Int Ed 59(4):1727\u20131734. https:\/\/doi.org\/10.1002\/anie.201914396","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"4970_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson DP, Smith BE, Burslem GM, Buhimschi AD, Hines J, Jaime-Figueroa S, Wang J, Hamman BD, Ishchenko A, Crews CM (2018) Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem biology 25(1):78\u201387. https:\/\/doi.org\/10.1016\/j.chembiol.2017.09.010","journal-title":"Cell Chem biology"},{"issue":"12","key":"4970_CR45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM (2019) Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discovery 18(12):949\u2013963. https:\/\/doi.org\/10.1038\/s41573-019-0047-y","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"4970_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.37349\/etat.2020.00018","volume":"1","author":"RI Troup","year":"2020","unstructured":"Troup RI, Fallan C, Baud MG (2020) Current strategies for the design of PROTAC linkers: a critical review. Explor Target Anti-tumor Therapy 1(5):273. https:\/\/doi.org\/10.37349\/etat.2020.00018","journal-title":"Explor Target Anti-tumor Therapy"},{"issue":"27","key":"4970_CR47","doi-asserted-by":"publisher","first-page":"11734","DOI":"10.1021\/jacs.9b13907","volume":"142","author":"R Gabizon","year":"2020","unstructured":"Gabizon R, Shraga A, Gehrtz P, Livnah E, Shorer Y, Gurwicz N et al (2020) Efficient targeted degradation via reversible and irreversible covalent PROTACs. J Am Chem Soc 142(27):11734\u201311742. https:\/\/doi.org\/10.1021\/jacs.9b13907","journal-title":"J Am Chem Soc"},{"key":"4970_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM (2019) PROteolysis TArgeting chimeras (PROTACs): past, present and future. Drug Discov Today Technol 31:15\u201327. https:\/\/doi.org\/10.1016\/j.ddtec.2019.01.002","journal-title":"Drug Discov Today Technol"},{"issue":"8","key":"4970_CR49","doi-asserted-by":"publisher","first-page":"eaay5064","DOI":"10.1126\/sciadv.aay5064","volume":"6","author":"M Reynders","year":"2020","unstructured":"Reynders M, Matsuura BS, B\u00e9routi M, Simoneschi D, Marzio A, Pagano M et al (2020) PHOTACs enable optical control of protein degradation. Sci Adv 6(8):eaay5064. https:\/\/doi.org\/10.1126\/sciadv.aay5064","journal-title":"Sci Adv"},{"key":"4970_CR50","doi-asserted-by":"publisher","first-page":"1098331","DOI":"10.3389\/fchem.2023.1098331","volume":"11","author":"H Jiang","year":"2023","unstructured":"Jiang H, Xiong H, Gu SX, Wang M (2023) E3 ligase ligand optimization of Clinical PROTACs. Front Chem 11:1098331. https:\/\/doi.org\/10.3389\/fchem.2023.1098331","journal-title":"Front Chem"},{"issue":"7","key":"4970_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang X, Crowley VM, Wucherpfennig TG, Dix MM, Cravatt BF (2019) Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat Chem Biol 15(7):737\u2013746. https:\/\/doi.org\/10.1038\/s41589-019-0279-5","journal-title":"Nat Chem Biol"},{"issue":"7","key":"4970_CR52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","volume":"15","author":"JN Spradlin","year":"2019","unstructured":"Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L et al (2019) Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat Chem Biol 15(7):747\u2013755. https:\/\/doi.org\/10.1038\/s41589-019-0304-8","journal-title":"Nat Chem Biol"},{"issue":"3","key":"4970_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acschembio.9b00092","volume":"14","author":"MJ Roy","year":"2019","unstructured":"Roy MJ, Winkler S, Hughes SJ, Whitworth C, Galant M, Farnaby W, Rumpel K, Ciulli A (2019) SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol 14(3):361\u2013368. https:\/\/doi.org\/10.1021\/acschembio.9b00092","journal-title":"ACS Chem Biol"},{"issue":"1","key":"4970_CR54","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz RP, Rui H, Dellamaggiore K, Ghimire-Rijal S, Choi K, Smither K, Amegadzie A, Chen N, Li X, Banerjee A, Chen Q (2023) Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun 14(1):4177. https:\/\/doi.org\/10.1038\/s41467-023-39904-5","journal-title":"Nat Commun"},{"issue":"10","key":"4970_CR55","doi-asserted-by":"publisher","first-page":"e202300163","DOI":"10.1002\/cbic.202300163","volume":"24","author":"JA Ward","year":"2023","unstructured":"Ward JA, Perez-Lopez C, Mayor\u2010Ruiz C (2023) Biophysical and computational approaches to study ternary complexes: a \u2018cooperative relationship\u2019to rationalize targeted protein degradation. ChemBioChem 24(10):e202300163. https:\/\/doi.org\/10.1002\/cbic.202300163","journal-title":"ChemBioChem"},{"issue":"3","key":"4970_CR56","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1021\/acs.jcim.0c01451","volume":"61","author":"N Bai","year":"2021","unstructured":"Bai N, Miller SA, Andrianov GV, Yates M, Kirubakaran P, Karanicolas J (2021) Rationalizing PROTAC-mediated ternary complex formation using Rosetta. J Chem Inf Model 61(3):1368\u20131382. https:\/\/doi.org\/10.1021\/acs.jcim.0c01451","journal-title":"J Chem Inf Model"},{"issue":"16","key":"4970_CR57","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1039\/d2cs00220e","volume":"51","author":"C Cao","year":"2022","unstructured":"Cao C, He M, Wang L, He Y, Rao Y (2022) Chemistries of bifunctional PROTAC degraders. Chem Soc Rev 51(16):7066\u20137114. https:\/\/doi.org\/10.1039\/d2cs00220e","journal-title":"Chem Soc Rev"},{"issue":"10","key":"4970_CR58","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/s41401-021-00852-9","volume":"43","author":"JJ Zhuang","year":"2022","unstructured":"Zhuang JJ, Liu Q, Wu DL, Tie L (2022) Current strategies and progress for targeting the undruggable transcription factors. Acta Pharmacol Sin 43(10):2474\u20132481. https:\/\/doi.org\/10.1038\/s41401-021-00852-9","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"4970_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17568919.2025.2476387","volume":"17","author":"Z Ge","year":"2025","unstructured":"Ge Z, Fan Z, He W, Zhou G, Zhou Y, Zheng M, Zhang S (2025) Recent advances in targeted degradation in the RAS pathway. Future Med Chem 17(6):693\u2013708. https:\/\/doi.org\/10.1080\/17568919.2025.2476387","journal-title":"Future Med Chem"},{"issue":"2","key":"4970_CR60","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/med.21992","volume":"44","author":"X Liang","year":"2024","unstructured":"Liang X, Ren H, Han F, Liang R, Zhao J, Liu H (2024) The new direction of drug development: Degradation of undruggable targets through targeting chimera technology. Med Res Rev 44(2):632\u2013685. https:\/\/doi.org\/10.1002\/med.21992","journal-title":"Med Res Rev"},{"issue":"3","key":"4970_CR61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40291-022-00586-2","volume":"26","author":"L Chen","year":"2022","unstructured":"Chen L, Wan X, Shan X, Zha W, Fan R, Chen et al (2022) Mol Diagn Ther 26(3):283\u2013291. https:\/\/doi.org\/10.1007\/s40291-022-00586-2","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"4970_CR62","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discovery 22(2):127\u2013144. https:\/\/doi.org\/10.1038\/s41573-022-00571-8","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"4970_CR63","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1039\/d5md00141b","volume":"16","author":"D Zhang","year":"2025","unstructured":"Zhang D, Wang Z, Inuzuka H, Wei W (2025) Proximity-induced membrane protein degradation for cancer therapies. RSC Med Chem 16(7):2881\u20132901. https:\/\/doi.org\/10.1039\/d5md00141b","journal-title":"RSC Med Chem"},{"issue":"95","key":"4970_CR64","doi-asserted-by":"publisher","first-page":"12852","DOI":"10.1039\/d1cc05715d","volume":"57","author":"W Cheng","year":"2021","unstructured":"Cheng W, Li S, Wen X, Han S, Wang S, Wei H, Song Z, Wang Y, Tian X, Zhang X (2021) Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia. Chem Commun 57(95):12852\u201312855. https:\/\/doi.org\/10.1039\/d1cc05715d","journal-title":"Chem Commun"},{"issue":"4","key":"4970_CR65","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acs.jcim.8b00872","volume":"59","author":"ML Drummond","year":"2019","unstructured":"Drummond ML, Williams CI (2019) In silico modeling of PROTAC-mediated ternary complexes: validation and application. J Chem Inf Model 59(4):1634\u20131644. https:\/\/doi.org\/10.1021\/acs.jcim.8b00872","journal-title":"J Chem Inf Model"},{"issue":"9","key":"4970_CR66","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/17460441.2021.1909567","volume":"16","author":"J Jim\u00e9nez-Luna","year":"2021","unstructured":"Jim\u00e9nez-Luna J, Grisoni F, Weskamp N, Schneider G (2021) Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov 16(9):949\u2013959. https:\/\/doi.org\/10.1080\/17460441.2021.1909567","journal-title":"Expert Opin Drug Discov"},{"issue":"13","key":"4970_CR67","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1021\/jacs.2c09387","volume":"145","author":"M Ignatov","year":"2023","unstructured":"Ignatov M, Jindal A, Kotelnikov S, Beglov D, Posternak G, Tang X, Maisonneuve P, Poda G, Batey RA, Sicheri F, Whitty A (2023) High accuracy prediction of PROTAC complex structures. J Am Chem Soc 145(13):7123. https:\/\/doi.org\/10.1021\/jacs.2c09387","journal-title":"J Am Chem Soc"},{"issue":"10","key":"4970_CR68","doi-asserted-by":"publisher","first-page":"2409173","DOI":"10.1002\/advs.202409173","volume":"12","author":"C Guan","year":"2025","unstructured":"Guan C, Gao J, Zou X, Shi W, Hao Y, Ge Y, Xu Z, Yang C, Bi S, Jiang X, Kang P (2025) A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKB\u03b1 Ubiquitination. Adv Sci 12(10):2409173. https:\/\/doi.org\/10.1002\/advs.202409173","journal-title":"Adv Sci"},{"issue":"24","key":"4970_CR69","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","volume":"27","author":"SJ Mandrekar","year":"2009","unstructured":"Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27(24):4027\u20134034. https:\/\/doi.org\/10.1200\/JCO.2009.22.3701","journal-title":"J Clin Oncol"},{"issue":"2","key":"4970_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","volume":"21","author":"A Honkala","year":"2022","unstructured":"Honkala A, Malhotra SV, Kummar S, Junttila MR (2022) Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discovery 21(2):99\u2013114. https:\/\/doi.org\/10.1038\/s41573-021-00301-6","journal-title":"Nat Rev Drug Discovery"},{"issue":"6","key":"4970_CR71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","volume":"14","author":"VB Kraus","year":"2018","unstructured":"Kraus VB (2018) Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol 14(6):354\u2013362. https:\/\/doi.org\/10.1038\/s41584-018-0005-9","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4970_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1042\/ETLS20210244","volume":"6","author":"Z Ahmed","year":"2022","unstructured":"Ahmed Z (2022) Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities. Emerg Top life Sci 6(2):215\u2013225. https:\/\/doi.org\/10.1042\/ETLS20210244","journal-title":"Emerg Top life Sci"},{"issue":"1","key":"4970_CR73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin Y, Seldin M, Lusis A (2017) Multi-omics approaches to disease. Genome Biol 18(1):83. https:\/\/doi.org\/10.1186\/s13059-017-1215-1","journal-title":"Genome Biol"},{"issue":"5","key":"4970_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg.2018.4","volume":"19","author":"KJ Karczewski","year":"2018","unstructured":"Karczewski KJ, Snyder MP (2018) Integrative omics for health and disease. Nat Rev Genet 19(5):299\u2013310. https:\/\/doi.org\/10.1038\/nrg.2018.4","journal-title":"Nat Rev Genet"},{"issue":"1","key":"4970_CR75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","volume":"6","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zhang H, Gao Y, Sun Y (2025) Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed 6(1):115. https:\/\/doi.org\/10.1186\/s43556-025-00340-0","journal-title":"Mol Biomed"},{"issue":"4","key":"4970_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/proteomes11040034","volume":"11","author":"T Ivanisevic","year":"2023","unstructured":"Ivanisevic T, Sewduth RN (2023) Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes 11(4):34. https:\/\/doi.org\/10.3390\/proteomes11040034","journal-title":"Proteomes"},{"key":"4970_CR77","doi-asserted-by":"publisher","unstructured":"Agogo-Mawuli PS, Afful EY, Fetse J, Siderovski DP Pharmacoproteomics and Drug Target Discovery. InPharmacoproteomics: Recent Trends and Applications 2024 Sep 1 (pp. 35\u201348). Cham: Springer Nature Switzerland https:\/\/doi.org\/10.1007\/978-3-031-64021-6_2","DOI":"10.1007\/978-3-031-64021-6_2"},{"issue":"8","key":"4970_CR78","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/jmcb\/mjab051","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Jia W (2021) Multi-omics profiling: the way toward precision medicine in metabolic diseases. J Mol Cell Biol 13(8):576\u2013593. https:\/\/doi.org\/10.1093\/jmcb\/mjab051","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"4970_CR79","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","volume":"6","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zhang H, Gao Y, Sun Y (2025) Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed 6(1):115. https:\/\/doi.org\/10.1186\/s43556-025-00340-0","journal-title":"Mol Biomed"},{"issue":"6","key":"4970_CR80","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/biom14060692","volume":"14","author":"P Du","year":"2024","unstructured":"Du P, Fan R, Zhang N, Wu C, Zhang Y (2024) Advances in integrated multi-omics analysis for drug-target identification. Biomolecules 14(6):692. https:\/\/doi.org\/10.3390\/biom14060692","journal-title":"Biomolecules"},{"key":"4970_CR81","doi-asserted-by":"publisher","unstructured":"Dhieb D, Mustafa D, Hassiba M, Alasmar M, Elsayed MH, Musa A, Zirie M, Bastaki K, Li H, Ma X, Shi D, Wang P (20252025) Harnessing pharmacomultiomics for precision medicine in diabetes: a comprehensive review. BiomedicinesBiomolecules 13(2):447. https:\/\/doi.org\/10.3390\/biomedicines13020447","DOI":"10.3390\/biomedicines13020447"},{"issue":"8","key":"4970_CR82","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","volume":"58","author":"S He","year":"2025","unstructured":"He S, Dong G, Sheng C (2025) Strategies for precise modulation of protein degradation. Acc Chem Res 58(8):1236\u20131248. https:\/\/doi.org\/10.1021\/acs.accounts.5c00003","journal-title":"Acc Chem Res"},{"issue":"6","key":"4970_CR83","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/bios15060336","volume":"15","author":"S Wang","year":"2025","unstructured":"Wang S, Cui X, Zhong Z, Zhang J (2025) Photoactivatable aptamer-based biosensors for point-of-care testing: advances and applications. Biosensors 15(6):336. https:\/\/doi.org\/10.3390\/bios15060336","journal-title":"Biosensors"},{"issue":"10","key":"4970_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14789450.2025.2560919","volume":"22","author":"S Alshehri","year":"2025","unstructured":"Alshehri S, Vitorino R, Saleh O, Al-Harthi S, Alahmadi A, Alotibi R, da Silva Rosa SC, Osama A, Magedeldin S, Alhattab D, Emwas AH (2025) Advances and applications of clinical proteomics in precision medicine. Expert Rev Proteomics 22(10):401\u2013420. https:\/\/doi.org\/10.1080\/14789450.2025.2560919","journal-title":"Expert Rev Proteomics"},{"issue":"5","key":"4970_CR85","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1042\/EBC20170041","volume":"61","author":"SJ Hughes","year":"2017","unstructured":"Hughes SJ, Ciulli A (2017) Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Essays Biochem 61(5):505\u2013516. https:\/\/doi.org\/10.1042\/EBC20170041","journal-title":"Essays Biochem"},{"issue":"21","key":"4970_CR86","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1080\/17568919.2024.2409618","volume":"16","author":"D Mi","year":"2024","unstructured":"Mi D, Huang A, Song J, Chen Y (2024) A long march for targeted protein degradation in the new era: expanding E3 ligases. Future Med Chem 16(21):2189\u20132191. https:\/\/doi.org\/10.1080\/17568919.2024.2409618","journal-title":"Future Med Chem"},{"key":"4970_CR87","doi-asserted-by":"publisher","unstructured":"Fung S, Vepdegestrant (2026) First Approval. Drugs. Aug 28:1-9 https:\/\/doi.org\/10.1007\/s40265-026-02372-4","DOI":"10.1007\/s40265-026-02372-4"},{"issue":"1","key":"4970_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/molecules31010033","volume":"31","author":"RK Acharyya","year":"2025","unstructured":"Acharyya RK, Kothapalli Y, Yarlagadda S, De CK, Allu SR, Roy J, Rej RK (2025) An update on clinically advanced PROTAC degraders and their synthesis. Molecules 31(1):33. https:\/\/doi.org\/10.3390\/molecules31010033","journal-title":"Molecules"},{"issue":"14","key":"4970_CR89","doi-asserted-by":"publisher","first-page":"16135","DOI":"10.1021\/acs.jmedchem.6c02076","volume":"69","author":"A Kumar","year":"2026","unstructured":"Kumar A, Ali S, Shen Q, Zhou J (2026) FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation. J Med Chem 69(14):16135\u201316142. https:\/\/doi.org\/10.1021\/acs.jmedchem.6c02076","journal-title":"J Med Chem"},{"issue":"9","key":"4970_CR90","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/cancers14092150","volume":"14","author":"JT J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen JT, Mollerup J (2022) Companion diagnostics and predictive biomarkers for MET-targeted therapy in NSCLC. Cancers 14(9):2150. https:\/\/doi.org\/10.3390\/cancers14092150","journal-title":"Cancers"},{"issue":"6","key":"4970_CR91","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.apsb.2024.01.010","volume":"14","author":"X Huang","year":"2024","unstructured":"Huang X, Wu F, Ye J, Wang L, Wang X, Li X, He G (2024) Expanding the horizons of targeted protein degradation: A non-small molecule perspective. Acta Pharm Sinica B 14(6):2402\u20132427. https:\/\/doi.org\/10.1016\/j.apsb.2024.01.010","journal-title":"Acta Pharm Sinica B"},{"issue":"2","key":"4970_CR92","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.5c01070","volume":"23","author":"AC Amalraj","year":"2026","unstructured":"Amalraj AC, Parthasarathy V (2026) Degraders on demand: engineering smart nanocarriers for PROTAC delivery. Mol Pharm 23(2):622\u2013638. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01070","journal-title":"Mol Pharm"},{"issue":"3","key":"4970_CR93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1389557516666161013104554","volume":"17","author":"G Anselmo Joanitti","year":"2017","unstructured":"Anselmo Joanitti G, Ganassin R, Correa Rodrigues M, Paulo Figueiro Longo J, Jiang CS, Gu J, Milena Leal Pinto S, de Fatima MA, Bentes de Azevedo R, Alexandre Muehlmann L (2017) Nanostructured systems for the organelle-specific delivery of anticancer drugs. Mini Rev Med Chem 17(3):224\u2013236. https:\/\/www.ingentaconnect.com\/content\/ben\/mrmc\/2017\/00000017\/00000003\/art00006","journal-title":"Mini Rev Med Chem"},{"issue":"4","key":"4970_CR94","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","volume":"17","author":"EW Syahputra","year":"2025","unstructured":"Syahputra EW, Lee H, Cho H, Park HJ, Park KS, Hwang D (2025) PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation. Pharmaceutics 17(4):501. https:\/\/doi.org\/10.3390\/pharmaceutics17040501","journal-title":"Pharmaceutics"},{"issue":"9","key":"4970_CR95","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/jfb14090437","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, Bansal KK, Vaidya A (2023) Lipid\u2013polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. J Funct Biomaterials 14(9):437. https:\/\/doi.org\/10.3390\/jfb14090437","journal-title":"J Funct Biomaterials"},{"issue":"10","key":"4970_CR96","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1097\/CM9.0000000000004036","volume":"139","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Guo J, Luo Q, Zhang X, Fan C, Feng S, Luo J, Fan Y, Wei Q, Li J, Qi P (2026) Biomimetic materials for medical applications. Chin Med J 139(10):1426\u20131463. https:\/\/doi.org\/10.1097\/CM9.0000000000004036","journal-title":"Chin Med J"},{"issue":"2","key":"4970_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/biom16020325","volume":"16","author":"B Faryal","year":"2026","unstructured":"Faryal B, Ul Abideen Z, Irfan M, Ahmed H, Jalilov F, Abduraximova L, Ashraf GA (2026) Targeted protein degradation in cancer: PROTACs, new targets, and clinical mechanisms. Biomolecules 16(2):325. https:\/\/doi.org\/10.3390\/biom16020325","journal-title":"Biomolecules"},{"issue":"18","key":"4970_CR98","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1111\/febs.15638","volume":"288","author":"X Chen","year":"2021","unstructured":"Chen X, Htet ZM, L\u00f3pez-Alfonzo E, Martin A, Walters KJ (2021) Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies. FEBS J 288(18):5231\u20135251. https:\/\/doi.org\/10.1111\/febs.15638","journal-title":"FEBS J"},{"issue":"749","key":"4970_CR99","doi-asserted-by":"publisher","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","volume":"15","author":"AM Kurimchak","year":"2022","unstructured":"Kurimchak AM, Herrera-Mont\u00e1vez C, Montserrat-Sangr\u00e0 S, Araiza-Olivera D, Hu J, Neumann-Domer R, Kuruvilla M, Bellacosa A, Testa JR, Jin J, Duncan JS (2022) The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci Signal 15(749):eabn2707. https:\/\/doi.org\/10.1126\/scisignal.abn2707","journal-title":"Sci Signal"},{"key":"4970_CR100","doi-asserted-by":"publisher","unstructured":"Machado-Neto JA (2026) Targeting undruggable cancer proteins: pharmacological challenges and emerging strategies. Translational Cancer Res 15(4). https:\/\/doi.org\/10.21037\/tcr-2025-1-2830","DOI":"10.21037\/tcr-2025-1-2830"},{"issue":"4","key":"4970_CR101","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) Targeted protein degraders crowd into the clinic. Nature reviews. Drug discovery 20(4):247\u2013250. https:\/\/doi.org\/10.1038\/d41573-021-00052-4","journal-title":"Drug discovery"},{"issue":"1","key":"4970_CR102","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL (2019) Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat Commun 10(1):3468. https:\/\/doi.org\/10.1038\/s41467-019-11429-w","journal-title":"Nat Commun"},{"issue":"1","key":"4970_CR103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","volume":"184","author":"SL Schreiber","year":"2021","unstructured":"Schreiber SL (2021) The rise of molecular glues. Cell 184(1):3\u20139. https:\/\/doi.org\/10.1016\/j.cell.2020.12.020","journal-title":"Cell"},{"issue":"7820","key":"4970_CR104","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR (2020) Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584(7820):291\u2013297. https:\/\/doi.org\/10.1038\/s41586-020-2545-9","journal-title":"Nature"},{"issue":"5","key":"4970_CR105","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","volume":"76","author":"D Takahashi","year":"2019","unstructured":"Takahashi D, Moriyama J, Nakamura T, Miki E, Takahashi E, Sato A et al (2019) AUTACs: cargo-specific degraders using selective autophagy. Mol Cell 76(5):797\u2013810e10. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.009","journal-title":"Mol Cell"},{"issue":"13","key":"4970_CR106","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","volume":"29","author":"SD Edmondson","year":"2019","unstructured":"Edmondson SD, Yang B, Fallan C (2019) Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019chemical space: Recent progress and future challenges. Bioorg Med Chem Lett 29(13):1555\u20131564. https:\/\/doi.org\/10.1016\/j.bmcl.2019.04.030","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"4970_CR107","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/d2cs00193d","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM (2022) PROTACs: past, present and future. Chem Soc Rev 51(12):5214\u20135236. https:\/\/doi.org\/10.1039\/d2cs00193d","journal-title":"Chem Soc Rev"},{"issue":"11","key":"4970_CR108","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.tips.2023.08.007","volume":"44","author":"G Sathe","year":"2023","unstructured":"Sathe G, Sapkota GP (2023) Proteomic approaches advancing targeted protein degradation. Trends Pharmacol Sci 44(11):786\u2013801. https:\/\/doi.org\/10.1016\/j.tips.2023.08.007","journal-title":"Trends Pharmacol Sci"},{"key":"4970_CR109","doi-asserted-by":"publisher","unstructured":"Shi Y, Shen Y, Zhang X, Zhu N, Ding Y, Yuan Y, Wang J (2025) The ubiquitin code of RAS proteins: Decoding its role in cancer progression. Iscience 28(8). https:\/\/doi.org\/10.1016\/j.isci.2025.113029","DOI":"10.1016\/j.isci.2025.113029"},{"key":"4970_CR110","doi-asserted-by":"publisher","unstructured":"McKinsey TA (2011) The biology and therapeutic implications of HDACs in the heart. Histone Deacetylases: the Biology and Clinical Implication. 6:57\u201378. https:\/\/doi.org\/10.1007\/978-3-642-21631-2_4","DOI":"10.1007\/978-3-642-21631-2_4"},{"issue":"13","key":"4970_CR111","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1039\/d1cs00762a","volume":"51","author":"Y Chen","year":"2022","unstructured":"Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q (2022) Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chem Soc Rev 51(13):5330\u20135350. https:\/\/doi.org\/10.1039\/d1cs00762a","journal-title":"Chem Soc Rev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04970-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04970-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04970-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:46:11Z","timestamp":1791524771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04970-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4970"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04970-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"18 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":5,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}